Creating new treatments for liver damage caused by acetaminophen overdose
Official title: Development of heparan sulfate-based therapeutics to treat inflammatory diseases
Funded at Glycan Therapeutics Corporation · NIH-11233689 · Data updated 2026-11-12
This study is looking at a new treatment called GLY-202 that could help people who have liver damage from taking too much acetaminophen, especially those who get help later than usual, by reducing inflammation and possibly avoiding the need for a liver transplant.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Glycan Therapeutics Corporation NIH-funded |
| Lab location | 1 site (Raleigh, UNITED STATES) |
| Project start | September 14, 2021 |
| Project end | July 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $50,000 |
| NIH project number | 3R44GM144019-03S1 |
| Project ID | NIH-11233689 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have experienced an acetaminophen overdose and are presenting late for treatment.
✕Less likely to help
Patients who have not ingested acetaminophen or those who are not experiencing liver toxicity will not benefit from this research.
What this research studies
This research focuses on developing a synthetic heparan sulfate oligosaccharide, GLY-202, to treat patients who experience liver toxicity from acetaminophen overdose, particularly those who seek treatment late. The project aims to optimize the compound to ensure it is easier and cheaper to produce while maintaining effectiveness. By targeting inflammation caused by the overdose, this new treatment could provide an alternative to liver transplantation for patients who miss the window for existing antidotes. The research involves preclinical testing and preparation for regulatory approval.
Why it matters
Potential benefit: If successful, this research could offer a new therapeutic option for patients suffering from acetaminophen-induced liver damage, potentially reducing the need for liver transplants.
How similar studies have gone: While the approach of using heparan sulfate oligosaccharides is innovative, similar strategies targeting liver inflammation have shown promise in other contexts, suggesting potential for success.
Where this research is happening
-
Glycan Therapeutics Corporation
Raleigh, United States Active
Researchers
- Principal investigator: Wang, Zhangjie — Glycan Therapeutics Corporation
- Study coordinator: Wang, Zhangjie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.